Alexander J Muller

List of Publications by Year
in descending order

63	7,700	101543	133252
papers	citations	36 h-index	59 g-index

66	66	66	8252
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. Journal of Immunology, 2022, 208, 571-581.	0.8	13
2	IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNÎ³/IL6 Balance to Promote Neovascularization. Cancer Immunology Research, 2021, 9, 514-528.	3.4	16
3	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 789473.	4.8	2
4	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8⁺ and CD4⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
5	Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology, 2020, 11, 1861.	4.8	70
6	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology, 2019, 41, 41-48.	6.1	198
7	Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry, 2019, 162, 455-464.	5.5	37
8	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	7.0	48
9	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons, 2018, 226, 596-603.	0.5	5
10	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive â€˜Coldâ€™ Tumors â€˜Hotâ€™. Trends in Cancer, 2018, 4, 38-58.	7.4	130
11	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
12	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology, 2018, 336, 175-203.	3.2	204
13	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology, 2018, 8, 370.	2.8	91
14	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research, 2017, 77, 1783-1812.	0.9	270
15	Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research, 2017, 77, 6795-6811.	0.9	433
16	IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine, 2016, 14, 74-82.	6.1	75
17	IDO2 Modulates T Cellâ€“Dependent Autoimmune Responses through a B Cellâ€“Intrinsic Mechanism. Journal of Immunology, 2016, 196, 4487-4497.	0.8	56
18	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. European Journal of Medicinal Chemistry, 2016, 108, 564-576.	5.5	33

#	Article	IF	Citations
19	Cardiacâ€Specific Disruption of Bin1 in Mice Enables a Model of Stressâ€•and Ageâ€Associated Dilated Cardiomyopathy. Journal of Cellular Biochemistry, 2015, 116, 2541-2551.	2.6	27
20	1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity, 2014, 47, 409-418.	2.6	18
21	IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology, 2014, 5, 585.	4.8	112
22	IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology, 2014, 26, 357-367.	4.0	168
23	IDO in Inflammatory Programming and Immune Suppression in Cancer. , 2014, , 311-346.		2
24	Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy, 2014, 63, 721-735.	4.2	423
25	IDO in Immune Escape. , 2013, , 565-581.		1
26	The Tumor-Selective Cytotoxic Agent Î²-Lapachone is a Potent Inhibitor of IDO1. International Journal of Tryptophan Research, 2013, 6, IJTR.S12094.	2.3	26
27	IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery, 2012, 2, 722-735.	9.4	280
28	Bin1 Attenuation Suppresses Experimental Colitis by Enforcing Intestinal Barrier Function. Digestive Diseases and Sciences, 2012, 57, 1813-1821.	2.3	15
29	Indoleamine 2,3-Dioxygenase Amino Acid Metabolism and Tumour-Associated Macrophages: Regulation in Cancer-Associated Inflammation and Immune Escape. , 2011, , 91-104.		0
30	Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biology and Therapy, 2011, 12, 1050-1058.	3.4	45
31	Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy, 2010, 59, 1655-1663.	4.2	57
32	Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase. Molecular Cancer Therapeutics, 2010, 9, 1864-1871.	4.1	27
33	Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy, 2010, 2, 293-297.	2.0	28
34	Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. Cancer Research, 2010, 70, 1845-1853.	0.9	65
35	Towards a Genetic Definition of Cancer-Associated Inflammation. American Journal of Pathology, 2010, 176, 2082-2087.	3.8	71
36	The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity. Journal of Immunology, 2009, 182, 7509-7517.	0.8	111

#	Article	IF	Citations
37	IDO recruits Tregs in melanoma. Cell Cycle, 2009, 8, 1818-1822.	2.6	27
38	BAR the door: Cancer suppression by amphiphysin-like genes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 25-36.	7.4	47
39	Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target. Journal of the American College of Surgeons, 2009, 208, 781-787.	0.5	118
40	Immune Escape: Role of Indoleamine 2,3-Dioxygenase in Tumor Tolerance. , 2009, , 257-283.		1
41	Indoleamine 2,3â€dioxygenase in Tâ€cell tolerance and tumoral immune escape. Immunological Reviews, 2008, 222, 206-221.	6.0	368
42	Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of Medicinal Chemistry, 2008, 51, 4968-4977.	6.4	148
43	Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1706-1718.	6.4	151
44	Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17073-17078.	7.1	214
45	Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research, 2008, 68, 1683-1690.	0.9	27
46	Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer. Current Cancer Drug Targets, 2007, 7, 31-40.	1.6	125
47	Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research, 2007, 67, 792-801.	0.9	557
48	Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research, 2007, 67, 100-107.	0.9	35
49	Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound <scp>d</scp>-1-Methyl-Tryptophan. Cancer Research, 2007, 67, 7082-7087.	0.9	453
50	Bin1 Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer. Cancer Research, 2007, 67, 7605-7612.	0.9	59
51	Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan. International Congress Series, 2007, 1304, 250-261.	0.2	1
52	Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition. , 2007, , 347-368.		0
53	Structureâ"Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 684-692.	6.4	161
54	Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nature Reviews Cancer, 2006, 6, 613-625.	28.4	239

#	Article	IF	Citations
55	Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine, 2005, 11, 312-319.	30.7	998
56	Marrying Immunotherapy with Chemotherapy: Why Say IDO?. Cancer Research, 2005, 65, 8065-8068.	0.9	105
57	Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 831-849.	3.4	100
58	Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology and Therapy, 2004, 3, 1236-1242.	3.4	23
59	Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene, 2003, 22, 3578-3588.	5.9	21
60	Targeted Disruption of the Murine Bin1/Amphiphysin II Gene Does Not Disable Endocytosis but Results in Embryonic Cardiomyopathy with Aberrant Myofibril Formation. Molecular and Cellular Biology, 2003, 23, 4295-4306.	2.3	118
61	Genetic mapping of the embryonal carcinoma transplantation resistance locus Gt(B6) to mouse Chromosome 8. Immunogenetics, 1999, 49, 949-956.	2.4	1
62	The gas5 gene is disrupted by a frameshift mutation within its longest open reading frame in several inbred mouse strains and maps to murine Chromosome 1. Mammalian Genome, 1998, 9, 773-774.	2.2	36
63	BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell, 1991, 66, 161-171.	28.9	362